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Abstract
Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but it is less
clear if this serious side effect is also related to other nucleoside reverse transcriptase inhibitors like zidovudine. We aimed to
determine whether zidovudine-sparing first-line antiretroviral therapy would lead to less lipoatrophy and other metabolic
changes than zidovudine-containing therapy.
Methodology/Principal Findings: Fifty antiretroviral therapy-naı¨ve HIV-1 infected men with an indication to start
antiretroviral therapy were included in a randomized single blinded clinical trial. Randomisation was between zidovudine-
containing therapy (zidovudine/lamivudine+lopinavir/ritonavir) and zidovudine-sparing therapy (nevirapine+lopinavir/
ritonavir). Main outcome measures were body composition assessed by computed tomography and dual-energy X-ray
absorptiometry scan and lipid profile before and after 3, 12, 24 months of antiretroviral therapy. In the zidovudine/
lamivudine+lopinavir/ritonavir group, from 3 months onward limb fat decreased progressively by 6846293 grams
(estimated mean6standard error of the mean)(p = 0.02) up to 24 months whereas abdominal fat increased, but exclusively
in the visceral compartment (+21.968.1 cm2, p = 0.008)). In contrast, in the nevirapine+lopinavir/ritonavir group, a
generalized increase in fat mass was observed. After 24 months no significant differences in high density lipoprotein and
total/high density lipoprotein cholesterol ratio were found between both treatment groups, but total and low density
lipoprotein cholesterol levels were higher in the nevirapine+lopinavir/ritonavir group (6.160.2 versus 5.360.2 and 3.660.1
versus 2.860.1 mmol/l respectively, p,0.05). Virologic response and safety were comparable in both groups.
Conclusions/Significance: Zidovudine/lamivudine+lopinavir/ritonavir, but not nevirapine+lopinavir/ritonavir in antiretrovi-
ral therapy-naı¨ve patients, is associated with lipoatrophy and greater relative intraabdominal lipohypertrophy, suggesting
that zidovudine/lamivudine contributes to both these features of lipodystrophy. These findings support to no longer
consider zidovudine/lamivudine as one of the preferred possible components of first-line antiretroviral therapy where
alternative treatments are available.
Trial Registration: ClinicalTrials.gov NCT 00122226
Citation: van Vonderen MGA, van Agtmael MA, Hassink EAM, Milinkovic A, Brinkman K, et al. (2009) Zidovudine/Lamivudine for HIV-1 Infection Contributes to
Limb Fat Loss. PLoS ONE 4(5): e5647. doi:10.1371/journal.pone.0005647
Editor: Srikanth Tripathy, National AIDS Research Institute, India
Received November 27, 2008; Accepted March 27, 2009; Published May 21, 2009
Copyright:  2009 van Vonderen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was sponsored by an independent scientific grant from Abbott International and Boehringer Ingelheim Corporate. The sponsors were
involved in the design of the study and in the review of the manuscript, but not in the conduct of the study, collection, management, analysis and interpretation
of the data; preparation and approval of the manuscript; or decision to publish.
Competing Interests: Marit van Vonderen reports having received reimbursement of travel costs for international conferences from Abbott, Boehringer
Ingelheim and UCB Pharma. Peter Reiss reports having received research grants and/or honoraria for consultancy/advisory boards or speaking engagements from
Gilead Sciences, Boehringer Ingelheim, Hoffman LaRoche, GlaxoSmithKline, Merck & Co, Bristol Myers Squibb, Tibotec and Theratechnologies. Sven Danner
reports having received honoraria for the advisory board from GlaxoSmithKline. Michiel van Agtmael declares having received honoraria for giving lectures and
participating in advisory boards/expert panels of Glaxo Smith Kline, Bristol Myers Squib, Boehringer Ingelheim and Merck and having received a research grant
from Abbott. Kees Brinkman declares having received honoraria for giving lectures and participating in advisory boards/expert panels of Glaxo Smith Kline, MSD,
Gilead, Roche, Pfizer and BMS. Matti Ristola reports having received research grants and/or honoraria for consultancy/advisory boards or speaking engagements
from Abbott, Boehringer Ingelheim, Hoffman LaRoche, GlaxoSmithKline, Merck & Co, Bristol Myers Squibb, Tibotec, Swedish Orphan, Pfizer and Schering-Plough.
Suzanne Geerlings reports having received honoraria for the advisory board from MSD. Elly Hassink, Ana Milinkovic and Arne van Eeden report no conflict of
interest.
* E-mail: M.vVonderen@vumc.nl
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5647
Introduction
Lipodystrophy is a common and serious problem associated
with HIV infection and its treatment [1]. The alterations in body
fat, consisting of lipoatrophy, the loss of subcutaneous fat from
arms, legs, buttocks and face, and fat accumulation in the
intraabdominal region, neck or trunk, are associated with
metabolic derangements including hyperlipidemia and insulin
resistance, which may contribute to increased cardiovascular risk
[1]. Furthermore, they may be stigmatizing and lead to
considerable psychological distress [2].
Stavudine, one of the thymidine analogue (TA) nucleoside
reverse transcriptase inhibitors (NRTI), has been associated with a
substantial risk for lipoatrophy development [3,4], and its use in
antiretroviral-naı¨ve patients is no longer recommended. Less
evidence is available concerning the effect on lipoatrophy
development of the TA-NRTI zidovudine as part of initial
treatment for HIV. One trial showed that the combination of
zidovudine and lamivudine (ZDV/3TC) resulted in less limb fat
loss than stavudine in combination with didanosine [5], when used
as part of combination antiretroviral therapy (cART).
To explore the role of NRTI in more detail, one strategy is to
evaluate alterations of body fat distribution and other metabolic
markers in NRTI sparing regimens. We therefore performed a
randomized trial comparing the effects of a TA-NRTI sparing
regimen composed of nevirapine with lopinavir/ritonavir with
those of a TA-NRTI containing regimen of ZDV/3TC with
lopinavir/ritonavir in prior cART naı¨ve patients. We hypothe-
sized that patients using ZDV/3TC would develop limb fat loss, in
contrast to those in the TA-NRTI sparing group. We currently
report the results of the planned primary analysis after 24 months
of follow-up.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1, Protocol
S1 and Protocol Amendment S1, S2, S3, S4, S5.
Study design and patients
The MEDICLAS (Metabolic Effects of DIfferent CLasses of
AntiretroviralS) trial is a multicenter, multinational, single-blinded,
randomized trial comparing the TA NRTI-containing regimen of
zidovudine/lamivudine (ZDV/3TC, 300/150 mg bd)+lopinavir/
ritonavir (LPV/r, 400/100 mg capsules bd) with the TA NRTI-
sparing regimen of nevirapine (NVP, 200 mg bd, following a 2-
week 200 mg od lead-in)+LPV/r (533/133 mg bd). To compen-
sate for any increased LPV/r clearance resulting from NVP-
associated hepatic enzyme induction, an increased dose of LPV/r
was used in combination with NVP to aim for comparable
therapeutic LPV plasma concentrations in both trial arms. Patients
were included between February 2003 and June 2005, the
complete 24 month follow-up ended in June 2007.
Eligible patients were antiretroviral-naı¨ve HIV-1-infected men,
18–70 years old, with an indication to start cART according to
international and national guidelines. Excluded were subjects with
extreme obesity (body mass index (BMI).35 kilogram (kg)/m2),
diabetes mellitus, a history of hyperlipidemia, or use of lipid
lowering drugs, nandrolone or testosterone. Patients were
recruited from HIV treatment centers in the Netherlands, Spain,
Finland and the United Kingdom. The study was approved by the
ethics committees of all participating centers, and each patient
provided written informed consent. Primary outcome measures
were changes in body composition, and metabolic abnormalities,
secondary outcome measures were virologic and immunologic
efficacy and overall safety.
Randomisation
At the central study coo¨rdinating center a treatment allocation
sequence (1:1 for ZVD/3TC/LPV/r and NVP/LPV/r) was
generated. Patients were allocated by minimization according to
their BMI (,25 and .25 kg/m2). Two separated minimization
schemes were used: one for patients that participated in the clamp
substudy (published previously [6]) and one for patients who did
not participate in this substudy.
Assessments
Fat distribution, fasting lipid profile and markers of glucose
metabolism were assessed at baseline and 3, 12, and 24 months
following start of treatment. These assessments of primary
outcome measures were performed by blinded investigators in
the Hospital Clinic Barcelona for Spanish participants, and in the
VU University Medical Center and the Academic Medical Center
in Amsterdam for all other participants. Assessments for routine
patient care were performed at the participating hospitals by
different physicians who were not blinded to treatment allocation.
Body composition
We measured BMI in kg/m2. Waist-to-hip ratio was calculated
from waist circumference, measured midway between the lowest
rib margin and the iliac crest, and hip circumference, measured at
the widest levels over the greater trochanters. Skinfoldthickness
using a skinfold caliper were measured at the level of the m. biceps
brachii, m. triceps brachii (both halfway the upper arm),
subscapular (just below the inferior angle of the scapula) and
supra-iliacal (just above the iliac crest, in the midaxillary line), all
on the non-dominant side of the body.
Arm circumference was measured halfway between the
acromion and olecranon in the non-dominant arm.
Fat weight was measured using a body impedance analyzer
(STA BIA, Akern Bioresearch, Italy), and fat percentage was
calculated from fat weight and total weight. These measurements
were performed by a single blinded investigator in the Nether-
lands, and another in Spain.
Limb fat, trunk fat, and lean weight were quantified by DEXA
(Hologic QDR-4500W, software version whole body v8.26A:5). A
standardized single slice abdominal CT-scan was performed from
which the area of visceral (VAT) subcutaneous (SAT), and total
adipose tissue (TAT) was determined. CT scans were evaluated at
the level of the third (L3, in the Netherlands) or fourth (L4, in
Spain) lumbar vertebra. Results are shown for the pooled L3 and
L4 scans, as changes in VAT, SAT and TAT over time at levels
L3 and L4 were highly correlated (in a subset of patients in whom
CT scans were performed at both levels at consecutive visits), and
results of the analyses after exclusion of L4 scans were comparable
to those of all scans combined.
At all visits lipodystrophy scores were calculated according to
the complete model of the international lipodystrophy case
definition [7].
Lipid profile and markers of glucose metabolism
Fasting lipid levels included total, high-density (HDL) and low-
density lipoprotein (LDL) cholesterol and triglycerides. LDL levels
were calculated with the Friedewald formula, if triglyceride values
were ,4.52 mmol/l. Insulin sensitivity was estimated by the
homeostasis model assessment of insulin resistance (HOMA),
calculated as (fasting insulin (mU/ml)6fasting glucose (mmol/l))/22.5.
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Virology, immunology and safety
Plasma HIV-1 RNA measurements (lower limit of quantification
50 copies/mL), CD4 cells, routine hematology and chemistry were
monitored at baseline, after 1 and 3 months of treatment, and every
three months thereafter. The Adult AIDS Clinical Trial Group
(ACTG) table for grading severity of adverse experiences was used
for reporting of clinical and laboratory adverse events [8].
LPV concentration was analysed centrally by validated HPLC
using diode array detection: coefficient of variation 1.6% at
1.98 mg/L and 1.7% at 7.96 mg/L; detection limit 0.008 mg/L.
LPV concentration ratios were calculated by dividing the
measured concentration by the expected concentration from a
reference curve [9].
Statistical analysis
Analyses were by modified intention-to-treat (intention to treat-
exposed), including all randomized patients who received at least one
dose of allocated treatment. Within group changes, between-group
differences in overall course and between-group differences at study
visits were analyzed using a linear model that takes repeated measures
into account (Proc Mixed in SAS), with correction for differences in
baseline values. The most appropriate covariate structure was
Figure 1. Patient disposition. ZDV/3TC/LPV/r zidovudine/lamivudine/lopinavir/ritonavir. NVP/LPV/r nevirapine/lopinavir/ritonavir.
doi:10.1371/journal.pone.0005647.g001
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selected based on the likelihood ratio test using a restricted maximum
likelihood model for estimations. Data are presented as estimated
means6standard error of the mean. Data that were not analyzed
longitudinally were compared between groups using Mann Whitney
U tests and Chi square/Fisher exact tests (where applicable).
Measures of body composition were correlated using Pearson
correlation. Alpha,0.05 was considered statistically significant.
SAS version 9.1 (SAS Institute, Cary, North Carolina, USA)(for the
longitudinal analysis) and SPSS statistical software version 15.0 (SPSS
Inc, Chicago, IL) were used for the analyses.
Results
Patient characteristics
Fifty patients were included between February 2003 and June
2005; 23 were randomly assigned to ZDV/3TC/LPV/r and 27 to
NVP/LPV/r. Two patients, one in each group, did not start
allocated therapy and were not included in the analysis (Figure 1).
Eight patients, 4 in each group, whose data were included in the
intent-to-treat analysis, prematurely discontinued the study (4 were
lost to follow-up, 3 withdrew consent and one patient died at
home, presumably due to an acute myocardial infarction). The
groups had comparable baseline demographic and HIV disease
characteristics (Table 1).
Antiretroviral therapy was modified in eight patients. In the
ZDV/3TC/LPV/r group, one patient switched from ZDV to
tenofovir after 3 months for anemia, one patient switched to
tenofovir/lamivudine/efavirenz after 4 months for anemia and
hypercholesterolemia and one patient switched from LPV/r to
NVP for hypercholesterolemia after 17 months. In the NVP/
LPV/r group, two patients switched to ZDV/3TC/NVP, one
after 3 months because of diarrhea and one after 24 months at his
own request. In three other patients NVP was replaced by
efavirenz because of hepatotoxicity and/or rash after 1, 2 and 5
months, respectively.
Body composition (Figure 2, Table 2)
Body composition at baseline was comparable between groups.
Body weight remained stable during 24 months in the ZDV/
3TC/LPV/r group, whereas it increased in the NVP/LPV/r group.
Lean weight remained stable in both groups. The changes in fat mass
showed significantly different patterns between the groups. Limb fat
remained stable during the first three months in the ZDV/3TC/
LPV/r group but progressively declined thereafter, with a total loss of
6846293 grams from 3 to 24 months (p=0.02). Total fat remained
unchanged in this group, resulting in a significant decrease of the limb
to total fat ratio (0.4760.008 to 0.4460.008; p=0.0015). In contrast,
in the NVP/LPV/r group, limb fat and total fat both increased, with
no change in the limb to total fat ratio. After 24 months, limb fat in
the ZDV/3TC/LPV/r group was 12236318 gram lower than in
the NVP/LPV/r group (p=0.0002).
Trunk fat and TAT increased in both groups during follow-up.
In the ZDV/3TC/LPV/r group VAT increased (+21.968.1 cm2
over 24 months (p = 0.008)), while SAT remained unchanged. In
contrast, in the NVP/LPV/r group, SAT and VAT both
increased after the first 3 months. As a result, the ratio of VAT
to SAT increased significantly in the ZDV/3TC/LPV/r group,
but remained unchanged in the NVP/LPV/r group, resulting in a
significant difference between groups after 24 months.
Of the 40 patients with complete lipodystrophy scores at 24
months, 3/18 (16.7%) in the ZDV/3TC/LPV/r group and 0/22
(0%) in the NVP/LPV/r group had lipodystrophy according to
the international case definition (Fisher exact p= 0.083).
Anthropometry and BIA findings were consistent with CT and
DEXA results (Figure 3, Table 2). Biceps skinfold thickness
decreased by 3.060.9 mm (p= 0.0008) and triceps by
4.061.2 mm (p= 0.0007) in the ZDV/3TC/LPV/r group, but
remained stable (biceps) or increased (triceps) in the NVP/LPV/r
group. After 24 months, patients in the ZDV/3TC/LPV/r group
had 3.861.0 mm (p= 0.0002) lower biceps and 6.461.3 mm
(p,0.0001) lower triceps skinfold thickness compared to those in
the NVP/LPV/r group. Arm circumference did not change in the
ZDV/3TC/LPV/r group but increased in the NVP/LPV/r
group. Changes in biceps and triceps skinfolds and arm
circumference were significantly correlated with changes in limb
fat (correlation coefficients 0.21, 0.39 and 0.48, respectively,
p = 0.007, 0.007 and ,0.0001). Hip circumference increased by
1.960.6 cm (p= 0.0019) in the NVP/LPV/r group, but remained
stable in the ZDV/3TC/LPV/r group, whereas waist circumfer-
ence increased in both groups (+2.060.9 cm (p= 0.03) and
+2.660.8 cm (p= 0.002) for the ZDV/3TC/LPV/r and NVP/
LPV/r groups respectively). This resulted in a significant increase
in the waist-to-hip ratio in the ZDV/3TC/LPV/r group, and no
change in the NVP/LPV/r group. Changes in waist circumfer-
ence were correlated with changes in TAT and VAT (correlation
coefficients 0.38 and 0.60, p,0.0001). The suprailiac skinfold
remained unchanged in the ZDV/3TC/LPV/r group, but
increased in the NVP/LPV/r group (+3.061.3 cm, p= 0.03),
and changes in suprailiac skinfold correlated with changes in SAT
(correlation coefficient 0.50, p,0.001).
Lipid profile (Table 2)
Total cholesterol increased significantly in both groups
(+23.265.8% in the ZDV/3TC/LPV/r group compared to
+36.565.2% in the NVP/LPV/r group; difference between
groups 13.367.8%, p= 0.09). HDL cholesterol increased signif-
Table 1. Baseline characteristics of the study population.
ZDV/3TC/LPV/r
(n=22)
NVP/LPV/r
(n=26)
Age (years) 38 (35–43) 43 (35–52)
Ethnic group
Black 1 (4.5%) 2 (7.7%)
Caucasian 19 (86.4%) 20 (76.9%)
Hispanic 0 (0%) 2 (7.7%)
Other 2 (9.1%) 2 (7.7%)
Mode of infection
Heterosexual 2 (9.1%) 3 (11.5%)
Heterosexual/MSM 0 (0%) 1 (3.8%)
MSM 20 (90.9%) 21 (80.8%)
Unknown 0 (0%) 1 (3.8%)
CDC category
A 14 (63.6%) 16 (61.5%)
B 3 (13.6%) 6 (23.1%)
C 5 (22.7%) 4 (15.4%)
CD4 cell count (106/l) 225 (170–280) 200 (120–360)
HIV-RNA (log 10 copies/ml) 5 (5–5) 5 (5–5)
Shown are median (interquartile range) or number (percentage).
ZDV/3TC/LPV/r zidovudine/lamivudine/lopinavir/ritonavir.
NVP/LPV/r nevirapine/lopinavir/ritonavir.
MSM men who have sex with men.
CDC Centers for Disease Control.
doi:10.1371/journal.pone.0005647.t001
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icantly by 32.867.4% in the ZDV/3TC/LPV/r group and by
38.866.6% in the NVP/LPV/r group (difference between groups
6.069.9%, p= 0.5). The total over HDL cholesterol ratio did not
change significantly over time in either of the groups. Whereas
LDL cholesterol did not increase in the ZDV/3TC/LPV/r group
(+11.567.4%, p= 0.13), a significant rise by 31.166.4% was
observed in the NVP/LPV/r group, difference between groups
19.669.8%, p= 0.05). Triglycerides increased in both groups
(+108630% and +81627% for the ZDV/3TC/LPV/r and
NVP/LPV/r group, respectively), with no significant difference
between groups.
Markers of glucose metabolism (Table 2)
There were no significant overall changes in fasting glucose,
insulin and HOMA in either of the treatment groups, with no
overall difference between groups.
Virologic and immunologic parameters and lopinavir
concentrations (Table 2)
Patients in both groups had similar immunologic and virologic
responses to cART. The median CD4 cell increase over 24
months was 280 (205–455) and 308 (191–410)6106 cells/l in the
Figure 2. Body composition by Dexa and CT. Shown are estimated means6standard error of the mean (mixed model repeated measures
analysis with correction for differences in baseline values). ZDV/3TC/LPV/r zidovudine/lamivudine/lopinavir/ritonavir. NVP/LPV/r nevirapine/lopinavir/
ritonavir. *p,0.05 between groups at visit. {p,0.05 overall difference between groups.
doi:10.1371/journal.pone.0005647.g002
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ZDV/3TC/LPV/r and NVP/LPV/r group, respectively. At 24
months, 17/22 (77%) of the patients in the ZDV/3TC/LPV/r
group and 21/26 (80%) in the NVP/LPV/r group had a plasma
HIV-RNA below 50 copies/ml. After 24 months there was a trend
for the LPV concentration to be greater in the NVP/LPV/r group
(8.0 (4.0–9.3) mg/l compared with 5.5 (3.8–6.9) mg/l for the
ZDV/3TC/LPV/r group (p= 0.065).
Adverse events
The proportion of patients who developed grade 3 and 4
adverse events was similar in both groups (10/22 (45.8%) in the
ZDV/3TC/LPV/r group and 14/26 (54.2%) in the NVP/LPV/r
group, p = 0.77). The most commonly observed adverse events
were hyperlipidemia (4/22 (18%) in the ZDV/3TC/LPV/r group
and 6/26 (23%) in the NVP/LPV/r group) and gastrointestinal
Table 2. Body composition, lipid profile, insulin sensitivity, virology/immunology and lopinavir levels.
ZDV/3TC/LPV/r NVP/LPV/r
Mo 0 Mo 3 Mo 12 Mo 24 Mo 0 Mo 3 Mo 12 Mo 24
CT/Dexa
Total arm fat (gram){ 1756682 1909688* 1715685 1680688*$ 1756674 1590677 1811677 1918679$
Total leg fat (gram){ 45906160 47506172 47696165 42956172*$ 45886144 46776149 52036149 52756155#$
Trunk fat (gram) 75226255 75276274 82376267 82716274#$ 74926229 69886238 82456238 84386247#$
Total fat (gram){ 138776425 141946456 147516446 142546457* 138476381 132656396 152696396 156436412#$
Lean body mass (gram) 533696421 531796440 538426424 538976430 534046431 544316453 542856453 539436465
TAT (cm2) 218.769.8 208.6610.8 230.2611.0 244.7610.8#$ 218.669.2 206.369.5 240.369.5 252.469.9#$
Anthropometry
Weight (kg) 74.660.7 74.760.7 75.960.7 75.660.7 74.660.6 74.960.6 76.960.6 77.260.7#$
Skinfold subscapular (mm) 20.261.1 21.661.2 21.061.2 20.361.2 20.261.0 20.961.1 22.761.1 20.861.1
Waist circumference (cm) 87.760.7 88.060.7 89.660.7 89.660.7# 87.760.6 88.060.6 90.460.6 90.260.7#$
Hip circumference (cm){ 95.960.5 95.760.5 96.560.5* 96.160.5* 95.960.5 96.260.5 98.060.5 97.860.5#$
Arm circumference (cm) 29.160.3 29.160.3 29.560.3 29.360.3 29.060.3 29.260.3 30.060.3 30.060.3#
BIA fat percentage (%) 18.660.6 18.460.6 18.460.6 18.160.6 18.660.5 18.260.6 19.760.6 19.760.6$
Lipid profile (fasting)
Total cholesterol (mmol/l){ 4.460.2 5.360.2* 5.460.2 5.360.2*# 4.560.2 5.860.2 5.960.2 6.160.2#
HDL cholesterol (mmol/l) 1.160.05 1.260.05 1.460.05 1.460.05#$ 1.160.05 1.460.05 1.460.05 1.460.05#
LDL cholesterol (mmol/l) 2.760.1 2.960.1 2.860.1 2.860.1 2.760.1 3.260.1 3.160.1 3.660.1#$
Total/HDL cholesterol 4.360.2 4.560.2 4.360.2 4.260.2 4.360.2 4.560.2 4.760.2 4.460.2
Triglycerides (mmol/l) 1.460.3 2.860.4 3.260.4 2.860.4# 1.460.3 2.760.3 3.260.3 2.460.3#
Apolipoprotein A (g/l) 1.060.04 1.260.04 1.260.04 1.460.05#$ 1.160.04 1.260.04 1.360.04 1.460.04#$
Apolipoprotein B (g/l) 0.960.04 1.060.05 1.060.05* 1.160.05# 0.960.04 1.160.05 1.260.04 1.260.05#
Insulin sensitivity (fasting)
Glucose 5.160.1 4.960.1 5.060.1 4.960.1 5.060.1 5.060.1 5.160.1 5.160.1
Insulin 5766.8 5267.3 6067.4 5467.5 6166.3 4567.0 5166.8 7167.0
HOMA 1.960.2 1.660.2 1.860.2 1.760.2 1.960.2 1.560.2 1.760.2 2.360.2
Virology/immunology
CD4 cell count (6106/l) 220 (170–264) 344 (250–440) 428 (360–557) 502 (385–685) 200 (120–360) 315 (210–520) 370 (284–606) 485 (340–625)
HIV-RNA (log 10 copies/ml) 5.1 (5.0–5.3) 2.1 (1.7–2.5) 1.7 (1.7–1.7) 1.7 (1.7–1.7) 4.9 (4.6–5.3) 1.7 (1.7–2.3) 1.7 (1.7–1.7) 1.7 (1.7–1.7)
Lopinavir levels
Lopinavir concentration (mg/l) 5.2 (3.1–6.9) 5.2 (3.7–6.6) 5.5 (3.8–6.9) 6.1 (3.7–6.9) 6.3 (5.3–6.9) 8.0 (4.0–9.3)
Lopinavir concentration ratio 1.2 (0.8–1.8) 1.2 (0.8–1.5) 1.0 (0.8–1.6) 1.2 (1.0–1.4) 1.4 (1.0–1.6) 1.6 (1.1–2.1)
Shown are estimated means6standard error of the mean (for variables included in the longitudinal analysis) or median (interquartile range) (for other variables).
ZDV/3TC/LPV/r zidovudine/lamivudine/lopinavir/ritonavir.
NVP/LPV/r nevirapine/lopinavir/ritonavir.
VAT visceral adipose tissue. SAT subcutaneous adipose tissue. TAT total adipose tissue. BIA body impedance analysis. HDL high density lipoprotein. LDL low density
lipoprotein. HOMA homeostasis model assessment of insulin resistance.
*p,0.05 between groups at each timepoint.
{p,0.05 overall comparison between groups over time.
#p,0.05 within group 0–24 months.
$p,0.05 within group 3–24 months.
doi:10.1371/journal.pone.0005647.t002
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complaints (4/22 (18%) in the ZDV/3TC/LPV/r group and 5/26
(19%) in the NVP/LPV/r group).
Discussion
The main finding from this trial is that ZDV/3TC contributed
to the development of limb fat atrophy in HIV-1-infected men not
previously exposed to cART. Whereas limb fat after 24 months
had increased by 8516255 grams in patients allocated to NVP/
LPV/r, a progressive loss of limb fat commencing after 3 months
and reaching a decline of 6846292 grams by 24 months was
observed in those randomized to ZDV/3TC/LPV/r. Moreover,
while patients randomized to NVP/LPV/r demonstrated a
generalized increase in fat mass, including both subcutaneous
and intraabdominal compartments, patients assigned to ZDV/
3TC/LPV/r experienced selective gain of visceral adipose tissue
without any change in the subcutaneous abdominal compartment,
which is characteristic for HIV-associated lipodystrophy. Consis-
tent with this observation, lipodystrophy according to the
International Case Definition was present in 3/18 patients
allocated to ZDV/3TC/LPV/r after 24 months follow-up, but
in none of the 22 evaluable patients allocated to NVP/LPV/r.
Although neither designed nor sufficiently powered to allow a
formal comparison of efficacy, our study demonstrated excellent
and comparable virological and immunological efficacy for both
regimens, consistent with other studies assessing LPV/r in
combination with a NNRTI in naı¨ve patients [10–12].
The rate of limb fat loss in patients on ZDV/3TC-containing
therapy in our study seems to be of a similar magnitude to what
has been reported previously from two randomized trials and one
Figure 3. Body composition by anthropometry. Shown are estimated means6standard error of the mean (mixed model repeated measures
analysis with correction for differences in baseline values). ZDV/3TC/LPV/r zidovudine/lamivudine/lopinavir/ritonavir. NVP/LPV/r nevirapine/lopinavir/
ritonavir. *p,0.05 between groups at visit. {p,0.05 overall difference between groups.
doi:10.1371/journal.pone.0005647.g003
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observational cohort study in previously treatment-naı¨ve individ-
uals [5,13,14]. One should be cautious however in directly
comparing the changes in limb fat in those studies with ours, given
the differences in both the frequency and timepoints at which
DEXA scans were performed in each of the studies. The role of
ZDV in lipoatrophy development is also supported by a study in
which patients on ZDV-containing regimens replaced ZDV with
either tenofovir or abacavir [15], and one in which patients were
randomized to either replace ZDV by tenofovir, or to continue
their existing ZDV-containing regimen [16].
Whether LPV/r may also have contributed to lipoatrophy,
similar to what has been shown for nelfinavir [5], cannot be ruled
out given that patients in both groups received LPV/r. However,
recent results from a randomized trial in which antiretroviral naive
subjects treated with dual NRTI’s plus LPV/r exhibited
significantly less loss of limb fat than those treated with two
NRTI’s plus efavirenz would argue against this [17].
Both treatments in our study resulted in similar degrees of
intraabdominal fat gain. This may represent an improvement in
patients’ general health as a result from suppressing HIV, although
a contribution from the use of LPV/r cannot be ruled out. Given
that all patients received LPV/r and after 24 months there was a
trend for patients on ZDV/3TC to have gained more intraab-
dominal fat, a contribution from these NRTI to this feature of
lipodystrophy can also not be discarded. The finding that visceral
fat accumulation in patients on ZDV/3TC/LPV/r was observed
in the context of stable SAT, whereas in patients on NVP/LPV/r
SAT increased in parallel with VAT would seem to support this.
In contrast to the advantages with regard to body composition,
the TA sparing regimen of NVP/LPV/r did not have an
unequivocal favorable impact on the lipid profile. Compared to
patients treated with ZDV/3TC/LPV/r, more patients developed
high total and LDL cholesterol levels according to NCEP criteria.
However, due to the rise in HDL cholesterol, the total/HDL
cholesterol ratio, a powerful predictor of cardiovascular risk [18],
did not increase over time. Our findings are consistent with the
dyslipidaemia described in patients switching to regimens of LPV/
r with efavirenz [19], but contrast with results from another small
trial which also included a regimen of NVP/LPV/r in treatment-
naive subjects [11]. Adjustment for differences in LPV levels
between treatment groups did not change the results of the
analysis, suggesting that this is not a likely explanation for the
higher total- and LDL-cholesterol levels found in the NVP/LPV/r
group. Differences in ritonavir exposure may have influenced the
results, but plasma (or intracellular) ritonavir concentrations levels
were not measured. HDL levels increased more in the NVP/
LPV/r group than in the ZDV/3TC/LPV/r group, but this
difference did not reach statistical significance, other than what
may have been expected from prior studies [20]. A possible
explanation for this is that our sample size was only sufficient to
demonstrate a statistically significant difference between groups if
this was 33% (or 0.29 mmol/l) or greater.
Several changes in anthropometric measures of body compo-
sition showed a good correlation with changes objectively
determined by DEXA and CT. This suggests that consecutive
measurements of skinfold thicknesses in the upper arm and of the
waist-to-hip ratio, may be able to reliably detect the onset of limb
fat loss and abdominal fat accumulation. This could potentially be
particularly relevant in resource limited settings, where it could
guide clinicians in the earlier detection of fat distribution changes
and timely modification of cART to try and prevent further
deterioration.
As novel antiretroviral drugs are being introduced, alternative
TA-sparing strategies become feasible, including regimens em-
ploying non-TA NRTI, PI – NNRTI combinations with other PI
than LPV/r, and also NRTI sparing regimens incorporating
CCR5- and integrase inhibitors. Long term prospective evaluation
of such alternative treatment strategies incorporating assessments
of body composition and metabolic effects may identify first-line
regimens which lack detrimental effects on both body composition
and lipid and glucose metabolism.
In conclusion, treatment with ZDV/3TC/LPV/r, in contrast to
NVP/LPV/r, during 24 months in cART-naı¨ve men was
associated with significant limb fat loss and visceral but not
subcutaneous abdominal fat accumulation. This adds to the
evidence to remove ZDV/3TC from the list of preferred
components of first-line antiretroviral regimens.
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